Whether seripalase (BRINEURA) can cure related diseases and scientific evaluation of its efficacy

Seripase (BRINEURA) is a drug that targets the neurodegenerative genetic disease - Neuronal Zero Acidase Deficiency (CLN2 type, also known as late-onset neuronal dystrophy type 2, LINCL) enzyme replacement therapy drug. It slows nerve cell damage by directly replenishing a specific enzyme (TPP1) that is lacking in the body, helping to break down accumulated lysosomal materials in the body. Although BRINEURA can significantly improve patients' motor and cognitive decline, there is currently no evidence that the drug can completely cure CLN2 type disease.

Clinical trial data show that BRINEURA’s therapeutic effect is mainly reflected in delaying disease progression. Patients who received regular intracerebroventricular injection therapy had a significantly slower rate of deterioration in motor function and language ability. Compared with a control group that did not receive treatment, the course of the disease was prolonged and the quality of life was improved to a certain extent. This effect is more pronounced in children who are diagnosed early and start treatment promptly, so early administration is considered a key factor in improving efficacy.

AlthoughBRINEURA has shown positive results in slowing disease progression, it still has certain limitations. Patients require long-term, regular treatment with intracerebroventricular injections, which not only increases the complexity of treatment but may also be associated with surgery-related risks. In addition, drug treatment does not reverse the neurological damage that has already occurred and therefore cannot fully restore a patient's lost motor or cognitive functions.

From the perspective of scientific evaluation, the efficacy of BRINEURA has been verified through multi-center clinical studies and long-term follow-up. It is especially effective in delaying the decline of motor and language functions. However, due to differences in the genetic characteristics and progression rate of the disease itself, there may be certain differences in individual patient outcomes. Therefore, BRINEURA is more suitable as a long-term management solution to delay the progression of the disease and improve the quality of life rather than a complete cure.

Reference materials:https://www.drugs.com/